摘要:
The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.
摘要:
Die Erfindung betrifft Dialkinverbindungen der Formel I worin n, m, R 1 , R 2 , X 1 , X 2 , X 3 , X 4 , Z 1 , Z 2 , A 1 A 2 , Q, Y 1 und Y 2 die in Anspruch 1 angegebene Bedeutung aufweisen.
摘要:
Disclosed are retiferol derivatives of formula (I): wherein X is > C=CH2 or -CH2-; Y and Z are independently of each other hydrogen, fluorine or hydroxy; A is -O(CH2)3-, -(CH2)2-(1,2-C6H4)-, -CH=CH-(1,2-C6H4)-, -C=C-(1,2-C6H4)-, -(CH2)2-CO-, -CH2-O-CO-, -CH2NHCO-, or -CH2NHCOCH2-; R1 is C1-C5-alkyl; R?2 and R3¿ are independently of each other alkyl or perfluoroalkyl; and R4 is hydrogen, hydroxy, C1-C5-alkyl or C1-C5-alkyl or C1-C5-alkoxy; the use of such compounds to treat or present hyperproliferative skin diseases such as psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; neoplastic diseases; disorders of the sebaceous glands such as acne and seborrhoic dermatitis; the use of these compounds in reversing the conditions associated with photodamage, particularly for the oral or topical treatment of the skin damaged through sun exposure, the effects of wrinkling, elastosis and premature ageing, furthermore a process for the manufacture of such compounds as well as pharmaceutical compositions containing such compounds.
摘要:
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要:
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Keams-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
摘要:
Novel and nonobvious compounds that function, alone or in combination, as nuclear hormone receptors for the stimulation and/or improvement of murine, mammalian skin. Specifically, beta-ionol analog and fatty acid analog compounds that are believed to function as RXR, RAR and/or PPAR receptor ligands to encourage skin differentiation and discourage excess skin proliferation. The present invention further relates to one or more products, consumer and otherwise, comprising the novel, nuclear hormone receptor ligands disclosed herein. The present invention additionally seeks to encompass methods of employing both the compounds of the present invention and the products incorporating the present compounds.
in der R¹ für H oder C₁-C₄-Alkyl, R² für C₁-C₄-Alkyl und R³ für eine durch Hydrolyse in eine Hydroxygruppe überführbare Ether-, Silylether- oder Acetal-Schutzgruppe, insbesondere für einen der Reste
stehen, sowie ein Verfahren zur Herstellung dieser Verbindungen durch Umsetzen eines Alkenins der allgemeinen Formel II
in einem inerten Lösungsmittel unter Mitverwendung von Lithiumamid mit einem Cyclohexenon der allgemeinen Formel III
und die Verwendung der Verbindungen der Formel I zur Herstellung von Astaxanthin.